Siu‐Long Yao

2.8k total citations
43 papers, 2.0k citations indexed

About

Siu‐Long Yao is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Siu‐Long Yao has authored 43 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 8 papers in Surgery. Recurrent topics in Siu‐Long Yao's work include Prostate Cancer Diagnosis and Treatment (17 papers), Prostate Cancer Treatment and Research (16 papers) and Advanced Breast Cancer Therapies (6 papers). Siu‐Long Yao is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (17 papers), Prostate Cancer Treatment and Research (16 papers) and Advanced Breast Cancer Therapies (6 papers). Siu‐Long Yao collaborates with scholars based in United States, Canada and India. Siu‐Long Yao's co-authors include Grace L. Lu‐Yao, Frank H. Valone, David J. Bzik, Vincent A. Memoli, George D. Sorenson, Peter C. Albertsen, Robert S. DiPaola, Thérèse A. Stukel, John Nemunaitis and Dirk F. Moore and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Annals of Internal Medicine.

In The Last Decade

Siu‐Long Yao

39 papers receiving 1.9k citations

Peers

Countries citing papers authored by Siu‐Long Yao

Since Specialization

Citations

This map shows the geographic impact of Siu‐Long Yao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Siu‐Long Yao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Siu‐Long Yao more than expected).

Fields of papers citing papers by Siu‐Long Yao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Siu‐Long Yao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Siu‐Long Yao. The network helps show where Siu‐Long Yao may publish in the future.

Co-authorship network of co-authors of Siu‐Long Yao

This figure shows the co-authorship network connecting the top 25 collaborators of Siu‐Long Yao. A scholar is included among the top collaborators of Siu‐Long Yao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Siu‐Long Yao. Siu‐Long Yao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Intra-articular MM-II for the treatment of knee osteoarthritis pain: Efficacy and safety results from a 26-week, phase 2b, placebo-controlled, double-blind, randomized dose-ranging trial 2025 ·Osteoarthritis and Cartilage ·Thomas J. Schnitzer, Xavier Chevalier, (unknown), Edith Lau, (unknown), (unknown), Richard C. Chou, (unknown), (unknown), Siu‐Long Yao, (unknown), (unknown), Asger Reinstrup Bihlet, Philip G. Conaghan	1
2	Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study 2024 ·Journal of the American Academy of Dermatology ·Kurt Gebauer, Lynda Spelman, Paul S. Yamauchi, Jerry Bagel, (unknown), (unknown), Iris Kopeloff, (unknown), Siu‐Long Yao, Howard Sofen	6
3	Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial 2024 ·Journal of the American Academy of Dermatology ·Howard Sofen, Kurt Gebauer, Lynda Spelman, Paul S. Yamauchi, Siu‐Long Yao, (unknown), Iris Kopeloff, (unknown), (unknown), (unknown), Jerry Bagel	0
4	Volume of intra-articular placebo injection has no effect on pain in knee osteoarthritic patients: Post hoc analyses from a phase 2b, double-blind, randomized trial 2024 ·Osteoarthritis and Cartilage ·(unknown), Xavier Chevalier, Asger Reinstrup Bihlet, Siu‐Long Yao, Richard C. Chou, (unknown), (unknown), (unknown), (unknown), Thomas J. Schnitzer, Philip G. Conaghan	1
5	POS0106 INTRA-ARTICULAR MM-II, A NOVEL SUSPENSION OF LARGE EMPTY MULTILAMELLAR LIPOSOMES, IN PAINFUL KNEE OSTEOARTHRITIS: A 26 WEEK PHASE 2B RANDOMIZED TRIAL 2023 ·Annals of the Rheumatic Diseases ·Philip G. Conaghan, (unknown), (unknown), (unknown), (unknown), Richard C. Chou, (unknown), (unknown), Siu‐Long Yao, (unknown), Asger Reinstrup Bihlet, Thomas J. Schnitzer	1
6	Vodobatinib, a potent, orally bioavailable brain-penetrating inhibitor of c-Abl as a potential neuroprotective agent for treatment of Parkinson disease 2023 ·Parkinsonism & Related Disorders ·Ryan R. Walsh, Steven P. Piccoli, (unknown), (unknown), Damon Love, Orest Hurko, Siu‐Long Yao, V. D. Ramanathan, (unknown)	0
7	Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson's disease 2023 ·Parkinsonism & Related Disorders ·Ryan R. Walsh, Nitin K. Damle, (unknown), Steven P. Piccoli, (unknown), Damon Love, Siu‐Long Yao, (unknown), Orest Hurko	17
8	Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial 2021 ·Journal of Controlled Release ·Josbert M. Metselaar, (unknown), Cornelis H. Wortel, Reinhard Bos, Jacob M. van Laar, Harald E. Vonkeman, René Westhovens, Twan Lammers, Siu‐Long Yao, (unknown), (unknown), J. W. J. Bijlsma	19
9	Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer 2015 ·European Urology ·Grace L. Lu‐Yao, Peter C. Albertsen, Dirk F. Moore, Yong Lin, Robert S. DiPaola, Siu‐Long Yao	42
10	Fifteen-Year Survival Outcomes Following Primary Androgen-Deprivation Therapy for Localized Prostate Cancer 2014 ·JAMA Internal Medicine ·Grace L. Lu‐Yao, Peter C. Albertsen, Dirk F. Moore, Weichung Joe Shih, Yong Lin, Robert S. DiPaola, Siu‐Long Yao	57
11	A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies 2013 ·Journal of Translational Medicine ·John Nemunaitis, Karen Small, Paul T. Kirschmeier, Da Zhang, Yali Zhu, Ying‐Ming Jou, Paul Statkevich, Siu‐Long Yao, Rajat Bannerji	105
12	Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer 2013 ·Lung Cancer ·Joe Stephenson, John Nemunaitis, Anil A. Joy, Julie Martin, Ying‐Ming Jou, Da Zhang, Paul Statkevich, Siu‐Long Yao, Yali Zhu, Haiyu Zhou, Karen Small, Rajat Bannerji, Martin J. Edelman	81
13	Does Primary Androgen-Deprivation Therapy Delay the Receipt of Secondary Cancer Therapy for Localized Prostate Cancer? 2012 ·European Urology ·Grace L. Lu‐Yao, Peter C. Albertsen, Hui Li, Dirk F. Moore, Weichung Joe Shih, Yong Lin, Robert S. DiPaola, Siu‐Long Yao	13
14	A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies 2008 ·Journal of Clinical Oncology ·Geoffrey I. Shapiro, Rajat Bannerji, Karen Small, Sherry R. Black, Paul Statkevich, Malaz Abutarif, Jennifer L. Moseley, Siu‐Long Yao, Chris H. Takimoto, Monica Mita	17
15	An evidence-based approach to prostate cancer follow-up 2003 ·Seminars in Oncology ·Siu‐Long Yao, Robert S. DiPaola	6
16	INTERVAL AFTER PROSTATE SPECIFIC ANTIGEN TESTING AND SUBSEQUENT RISK OF INCURABLE PROSTATE CANCER 2001 ·The Journal of Urology ·Siu‐Long Yao, Grace L. Lu‐Yao	16
17	A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. 2001 ·PubMed ·Carolyn D. Britten, Eric K. Rowinsky, Steven L. Soignet, Amita Patnaik, Siu‐Long Yao, Paul Deutsch, Yih Lee, Robert B. Lobell, Kathryn Mazina, (unknown), (unknown), David R. Spriggs	65
18	Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy—a population-based study 1999 ·Urology ·Grace L. Lu‐Yao, Peter C. Albertsen, Joan L. Warren, Siu‐Long Yao	74
19	Population-Based Study of Relationships Between Hospital Volume of Prostatectomies, Patient Outcomes, and Length of Hospital Stay 1999 ·JNCI Journal of the National Cancer Institute ·Siu‐Long Yao, Grace L. Lu‐Yao	135
20	Population-based study of long-term survival in patients with clinically localised prostate cancer 1997 ·The Lancet ·Grace L. Lu‐Yao, Siu‐Long Yao	292

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact